# ‘Too good to be true’: Biotech company’s paper on Parkinson’s retracted for data manipulation

Source: [Retraction Watch](https://retractionwatch.com/2026/11/16/cell-reports-denali-therapeutics-neurodegeneration/) · 2026-11-16 · Science & Society
Page: https://themorning.science/story/too-good-to-be-true-biotech-company-s-paper-on-parkinson-s-retracted-for-data-ma-6153a42019c66efc
Kind: research · Impact: medium

## In brief

- Cell Reports, a Cell Press journal, has retracted a Parkinson's disease paper.
- The retraction notice says a coauthor found that first author Madhuja Samaddar changed data points to reduce variation in the work.
- The paper came from a biotech company, which the source URL identifies as Denali Therapeutics.

## Why it matters

A retraction for manipulated data means the paper's findings on Parkinson's disease should no longer be relied on, and it is a reminder that data integrity checks can catch fabricated results.

## Coverage

- [‘Too good to be true’: Biotech company’s paper on Parkinson’s retracted for data manipulation](https://retractionwatch.com/2026/11/16/cell-reports-denali-therapeutics-neurodegeneration/) — Retraction Watch, 2026-11-16

Tags: parkinsons, retraction, research-integrity, data-manipulation, neurodegeneration

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
